RI(dl)-2 TFA

TargetMol
Product Code: TAR-T28536
Supplier: TargetMol
CodeSizePrice
TAR-T28536-25mg25mg£1,010.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28536-50mg50mg£1,484.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28536-100mg100mg£2,223.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C

Images

1 / 1

Further Information

Bioactivity:
RI(dl)-2 TFA is a potent and selective RAD51-mediated D-loop formation inhibitor with an IC 50 of 11.1 uM which also inhibits homologous recombination(HR) activity in human cells with IC50 of 3.0 uM[1].
CAS:
1902146-75-1
Molecular Weight:
287.366
Purity:
0.98
SMILES:
CCNc1ccc(cc1)-c1nc2ccccc2n2cccc12

References

Castillo JJ, Jurczyszyn A, Brozova L, Crusoe E, Czepiel J, Davila J, Dispenzieri A, Eveillard M, Fiala MA, Ghobrial IM, Gozzetti A, Gustine JN, Hajek R, Hungria V, Jarkovsky J, Jayabalan D, Laubach JP, Lewicka B, Maisnar V, Manasanch EE, Moreau P, Morgan EA, Nahi H, Niesvizky R, Paba-Prada C, Pika T, Pour L, Reagan JL, Richardson PG, Shah J, Spicka I, Vij R, Waszczuk-Gajda A, Gertz MA. IgM Myeloma: A Multicenter Retrospective Study of 134 Patients. Am J Hematol. 2017 Apr 6. doi: 10.1002/ajh.24753. [Epub ahead of print] PubMed PMID: 28383205. Kim JH, Lee SM, Son YK, Kim SE, An WS. Resistive index as a predictor of renal progression in patients with moderate renal dysfunction regardless of angiotensin converting enzyme inhibitor or angiotensin receptor antagonist medication. Kidney Res Clin Pract. 2017 Mar;36(1):58-67. doi: 10.23876/j.krcp.2017.36.1.58. Epub 2017 Mar 31. PubMed PMID: 28392998; PubMed Central PMCID: PMC5331976. Yuan Y, Yang X, Gong D, Liu F, Hu W, Cai W, Huang J, Yang M. Investigation for terminal reflection optical fiber SPR glucose sensor and glucose sensitive membrane with immobilized GODs. Opt Express. 2017 Feb 20;25(4):3884-3898. doi: 10.1364/OE.25.003884. PubMed PMID: 28241599. Mongraw-Chaffin M, LaCroix AZ, Sears DD, Garcia L, Phillips LS, Salmoirago-Blotcher E, Zaslavsky O, Anderson CA. A prospective study of low fasting glucose with cardiovascular disease events and all-cause mortality: The Women's Health Initiative. Metabolism. 2017 May;70:116-124. doi: 10.1016/j.metabol.2017.02.010. Epub 2017 Feb 16. PubMed PMID: 28403935; PubMed Central PMCID: PMC5402725.